Sibelium

Selected form

Flunarizine

Method of action: Other Nervous System Drugs

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sibelium

Property	Description
Active ingredient	Flunarizine (typically as Flunarizine dihydrochloride)
Form	Tablet or Capsule
Pharmacological class	Selective calcium antagonist
General purpose	Prophylaxis of migraine, relief of vertigo
Origin	Synthetic (Piperazine derivative)

Sibelium is a prescription-only medicine defined by its active ingredient, Flunarizine, which is clinically recognized for its use in the prophylaxis of migraine and the symptomatic management of vertigo. It is fundamentally classified as a selective calcium antagonist, belonging to the larger pharmacological class of calcium channel blockers.

What is Sibelium and What Type of Medicine is it?

Sibelium is the established trade name for the medication containing Flunarizine, the International Nonproprietary Name (INN) for the active substance. This substance is categorized as a selective calcium antagonist because its therapeutic action focuses on stabilizing the vascular and vestibular systems. The compound is a synthetic piperazine derivative, a chemical family utilized in the treatment of specialized vascular and neurological conditions. Its specific mechanism differentiates it within the calcium channel blocker class, as it targets vascular tone stabilization with distinct cerebroselective properties.

Composition and Physical Form of Flunarizine

The primary active ingredient in Sibelium is Flunarizine, often prepared as its salt, Flunarizine dihydrochloride. This is a single-ingredient product supplied for oral administration. The medication is provided in solid pharmaceutical preparations, such as tablets or capsules. As a synthetic agent, the precise chemical composition ensures consistent quality and bioavailability, which is necessary for maintaining the long-term, stable plasma concentrations required for effective prophylaxis.

What is the General Purpose of Sibelium?

The general purpose of Sibelium is to provide stabilization and prophylaxis against episodes stemming from underlying vascular or neurological imbalances. It is primarily employed as a prophylactic treatment for migraine and for the symptomatic treatment of vertigo. Due to its vestibulosuppressive effect, it is an option for patients experiencing chronic dizziness or spinning sensations related to vertigo, serving a specific, typical use scenario in neurological care.

What side effects are possible with Sibelium?

Possible side effects and safety information

The safety profile of Sibelium (flunarizine) is officially documented by government regulatory bodies, classifying adverse reactions by frequency and physiological system. This information establishes the known risks associated with the medicine.

Frequency and Organ System Classification

Adverse reactions are grouped according to their reported incidence rate in regulatory documentation, consistent with standard frequency classifications.

Frequency Classification	System-Organ Class Examples
Very Common (ge 1/10)	Metabolism and Nutrition Disorders (e.g., Weight Increased)
Common (ge 1/100 to < 1/10)	Psychiatric Disorders (Depression, Increased Appetite); Nervous System Disorders (Somnolence)
Uncommon (ge 1/1,000 to < 1/100)	Gastrointestinal Disorders (e.g., Nausea, Vomiting); Skin and Subcutaneous Tissue Disorders (e.g., Urticaria)
Not Known	Nervous System Disorders (Extrapyramidal Disorders); Reproductive System Disorders (Galactorrhoea)

Clinically Significant Safety Considerations

Regulatory texts identify Depressive Symptoms and Extrapyramidal Symptoms as clinically significant adverse experiences that warrant assessment. Extrapyramidal symptoms encompass movement disorders such as Parkinsonism, tremor, rigidity, and dyskinesia. The risk of these serious reactions is associated with chronic administration.

Population-Specific Notes and Restrictions

Safety notes specify that Older Adults may be at an increased risk of developing extrapyramidal and depressive symptoms. The medicine is contraindicated for use in patients with a history of depressive illness or pre-existing Parkinson's Disease or other Extrapyramidal Disorders. Somnolence is a nervous system effect that is often observed particularly at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Flunarizine (Sibelium) overdose is based strictly on descriptions documented in official government regulatory sources.

Documented Overdose Manifestations

In cases of overdosage, the officially reported clinical signs affect the Central Nervous System (CNS) and cardiovascular system. These manifestations include sedation, agitation, and tachycardia (rapid heart rate). Exposure to massive doses, significantly exceeding the therapeutic range, has been associated with severe outcomes, including profound CNS depression, which may lead to coma and respiratory depression.

Emergency Actions Mandated by Regulators

Action Category	Official Guidance
Immediate Action	Seek immediate medical attention or contact a poison control center if overdose is suspected.
Antidote Availability	No specific antidote is known for Flunarizine overdose.
Management Measures	Treatment is symptomatic and supportive. Administration of activated charcoal may be considered, if appropriate and performed shortly after ingestion.

If overdose is suspected or a massive ingestion has occurred, urgent medical help is required. Because no specific antidote is available, management focuses on close observation and supportive measures to address the documented clinical manifestations and maintain vital functions.

Therapeutic Uses of Sibelium

Sibelium (flunarizine) is used as a prophylactic treatment for certain neurological and vestibular conditions. It is indicated for the management of chronic symptoms, and is not for the treatment of acute events. Its use is indicated for two main therapeutic areas: the prevention of recurring migraine attacks and the symptomatic management of vestibular disorders.

Clinical indications include prophylaxis of classic or common migraine and the symptomatic treatment of vestibular vertigo.

Its use may be associated with a potential to decrease the frequency and lessen the severity of migraine episodes. For individuals with vestibular issues, its use is associated with the potential to reduce symptoms such as spinning and dizziness.

Quick Fact: May assist in the management of dizziness and spinning

Eligibility and Restrictions for Use

Sibelium (Flunarizine) eligibility is strictly defined by regulatory authorities, with use typically established for adults seeking migraine prophylaxis or vertigo treatment. Non-eligibility is determined by official contraindications, age restrictions, and physiological status.

Contraindicated Populations

Use of this medicine is formally contraindicated in patients with a current depressive illness or a history of recurrent depression. Absolute prohibition also applies to individuals with pre-existing Parkinson's disease or other extrapyramidal disorders. Patients with known hypersensitivity to flunarizine or specific hereditary metabolic disorders (such as galactose intolerance) must not use the medication.

Restricted and Non-Recommended Use

The medicine is generally not recommended for the pediatric population (under 18 years of age) because safety and efficacy have not been formally established by regulators for migraine prophylaxis. Use is not recommended during pregnancy and while breastfeeding. Special regulatory caution is required for older adults (typically 65 years and over) due to increased risk of developing neurological symptoms, and for patients with compromised liver function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Sibelium (flunarizine) through specific pharmacokinetic (PK) and pharmacodynamic (PD) patterns, without listing mandatory contraindicated drug-drug combinations. All documented interactions strictly concern either altered drug clearance or additive effects with certain substance classes.

Pharmacokinetic Interactions Leading to Altered Exposure

The co-administration of Sibelium with enzyme-inducing anticonvulsants, such as Carbamazepine and Phenytoin, is associated with enhanced metabolism and resulting lower flunarizine plasma concentrations. This reduced exposure is specifically noted in patients with epilepsy who are concurrently taking Anti-epileptic Drugs (AEDs). Conversely, co-administration with Topiramate formally results in a documented, modest increase in flunarizine systemic exposure (AUC), as stated in regulatory product information. Sibelium does not appear to reciprocally affect the clearance of these anticonvulsants.

Pharmacodynamic and Other Documented Interactions

The most significant pharmacodynamic interaction is the additive CNS depressant effect observed with Alcohol, Hypnotics, and Tranquilizers, which can lead to excessive drowsiness. Separately, the concurrent use with anti-hypertensive drugs may necessitate a dosage adjustment of the anti-hypertensive drugs. Furthermore, galactorrhoea has been formally reported in women using oral contraceptives within the first two months of treatment with flunarizine.

Mechanism of Action

How Sibelium Works

Sibelium (flunarizine) functions primarily as a selective calcium entry blocker across various excitable cell membranes. Its principal molecular targets are voltage-gated calcium channels, particularly the T-type ( Ca V3) channels and, to a lesser extent, the L-type ( Ca V1) channels found in vascular smooth muscle and neurons.

The compound is proposed to interact with these channels in a use-dependent manner, physically plugging the channel pore to inhibit the influx of extracellular calcium ions. This reduction in intracellular calcium concentration modulates various cellular processes, including muscle cell contractility and neuronal excitability. The effect on smooth muscle causes dilation of systemic and coronary arteries, resulting in a decrease in total peripheral resistance and systemic arterial tension. Additionally, the drug exhibits secondary activity, acting as an antagonist at histamine ( H1) receptors and demonstrating weak dopamine ( D2) receptor blocking properties. Flunarizine is also noted for its ability to stabilize the integrity of the blood-brain barrier during transient ischemic events.

Dosage and Administration Information

How to Use Sibelium

Sibelium (flunarizine) administration follows a structured, phased protocol focusing on oral intake and specific time-dependent schedules.

Administration Scope

The medication is supplied as capsules or tablets and is for oral administration.

Instruction	Detail
Dosing Schedule	Initial doses are 10 mg once daily for standard adults (18-64 years) or 5 mg once daily for older adults (65 years and over) and adolescents (12 years and over).
Timing	The dose is typically taken at night (in the evening) once a day.
Duration and Cycles	Treatment is often organized into defined trial periods. For migraine prophylaxis, use is assessed after two months; if no significant improvement is seen, the administration must be discontinued.
Maintenance Phase	If the patient is a responder, the regimen may transition to an intermittent schedule, such as 5 consecutive days of treatment followed by 2 drug-free days per week.

Population-Specific Procedural Rules

Procedural adjustments are established for certain patient groups. A lower starting dose of 5 mg daily is specified for older adults. Additionally, caution and potential dose reduction are procedural steps to be considered when administering flunarizine to patients with hepatic impairment, as the drug is metabolized by the liver. The requirement to discontinue the medicine if a patient is designated a non-responder after the specified trial duration is a critical procedural condition defined in the use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sibelium

The clinical research conducted on Flunarizine (Sibelium) focuses on two primary areas: recurring migraine attacks and symptoms associated with vestibular vertigo. This overview describes the research structure and its limitations, and should not be used as clinical advice.

Evidence for Use in Migraine Prophylaxis

The research base for migraine prophylaxis includes Randomized Controlled Trials (RCTs) and Systematic Reviews that explore outcomes in adults and adolescents. Studies primarily examine changes in migraine attack frequency and the assessment of migraine-related disability. Comparative research has also been evaluated in trials directly comparing Flunarizine against a placebo or specific active comparator treatments. Findings from reviews describe patterns where research explored attack frequency as a primary outcome, but the evidence quality varies across studies due to the inclusion of older trials that may not adhere to modern standards.

Evidence for Use in Vestibular Vertigo

Research investigating symptoms associated with vestibular vertigo comprises a mix of controlled clinical trials and observational studies. Researchers monitored outcomes related to functional imbalance, such as changes in the frequency and intensity of vertigo attacks. Evidence for this indication is often considered heterogeneous, meaning the methods and endpoints used were inconsistent across the available studies. Certainty remains low due to reliance on studies with modest sample sizes.

Long-Term Outcomes and Research Gaps

Studies focused on long-term outcomes that persist over extended periods (beyond 12 months) are limited. Data for sustained change remains insufficient in recent systematic reviews. While research has been conducted on special populations like children and older adults, findings for these groups are often based on smaller trials, and data are insufficient to establish wide-ranging findings. The overall research base is characterized by many older trials, contributing to uncertainty when generalizing the patterns of measured outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Sibelium (FAQ)

Q: Is Sibelium a type of painkiller?

A: Regulatory documents classify Sibelium as a selective calcium antagonist and prophylactic treatment. This means it is specifically intended to prevent episodes, such as migraines, and is not used to relieve acute pain once an episode has already started.

Q: What is the difference between Sibelium and over-the-counter headache pills?

A: Sibelium is used for the long-term prevention, or prophylaxis, of certain conditions. Official warnings state that it is not suitable for stopping an acute attack. Many over-the-counter headache pills, by contrast, are intended to treat the pain during an acute episode.

Q: Is Sibelium the same type of drug as Propranolol?

A: Official documents classify Sibelium as a selective calcium entry blocker and a piperazine derivative. This pharmacological classification is distinct from other common preventive drugs, such as beta-blockers like Propranolol, which work through a different mechanism.

Q: Can Sibelium be used by teenagers?

A: Regulatory documents include a specific daily dose for adolescents aged 12 years and over when used for migraine prophylaxis. However, use in the pediatric population (under 18) is often considered conditional, and official guidance recommends that use be discussed with a healthcare provider.

Q: Can Sibelium make you feel more tired than normal?

A: Regulatory documents list fatigue and tiredness as common, possible side effects. These effects may increase progressively during treatment and are noted to be distinct from general drowsiness.

Q: What kind of research exists on Sibelium for its main purpose?

A: The research base for Sibelium includes both Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily examine outcomes related to the frequency of migraine attacks and the symptomatic management of vestibular vertigo.

Q: Can I drive a car while taking Sibelium?

A: Official regulatory warnings caution patients against engaging in activities that require alertness or rapid, precise responses, such as driving motor vehicles or operating machinery. This caution is due to the potential for drowsiness or sedation.

Q: Is there a generic version of Sibelium available?

A: Sibelium is a trade name, but the active substance is flunarizine, which is the International Nonproprietary Name (INN). Medications containing flunarizine may be available and marketed under different trade names in various countries.

Q: Is Sibelium commonly prescribed alongside other preventive medications?

A: Regulatory documents note pharmacokinetic interactions with certain anti-epileptic and anticonvulsant drugs. This indicates that flunarizine may be administered concurrently with other treatments, and regulatory documents specify that careful monitoring is required when used in this manner.

Q: What should I do if a side effect of Sibelium bothers me?

A: Regulatory information states that patients should seek advice from their doctor if they experience any bothersome side effects. Treatment may need to be discontinued, particularly if severe symptoms like depression or extrapyramidal symptoms occur.

Q: Does Sibelium interact with alcohol?

A: Official regulatory warnings specifically advise caution regarding alcohol intake. Simultaneous consumption of alcohol may aggravate the known side effect of drowsiness or sedation.

Q: How quickly should I notice any effects from Sibelium?

A: Sibelium is a prophylactic medicine, not a quick-acting treatment. Official documents indicate that the full preventative effect may take several weeks, or even up to two months, to be reached.

Q: What happens if I forget to take a dose of Sibelium?

A: If a dose is forgotten, regulatory instructions advise the patient to skip that missed dose. The next dose should then be taken at the usual time, without taking a double dose to compensate.

Q: Is Sibelium safe for long-term use?

A: Official documents note that the risk of certain neurological and psychiatric effects, such as extrapyramidal and depressive symptoms, is associated with chronic administration. For this reason, official guidance specifies that patients on long-term treatment should be seen at regular intervals for monitoring.

Q: What are the most common reasons a person stops taking Sibelium?

A: Official documents specify that administration must be discontinued if certain side effects occur. These include depressive symptoms, extrapyramidal symptoms (movement disorders), or progressively increasing fatigue that becomes unacceptable.

Q: What is the maximum duration Sibelium is typically taken for?

A: The official protocol notes that if the medicine proves beneficial after the initial trial period, it is often used for at least six months. Following this period, official protocol notes that the need for continued maintenance should be reviewed by a healthcare provider.

Q: Can Sibelium affect my mood or emotional state?

A: Official documents list depression and low mood as a common side effect of the medicine. Official guidance states that a history of depressive illness is a formal contraindication for use.

Q: Do older adults react differently to Sibelium than younger adults?

A: Official documents state that older adults (typically 65 years and over) may be at an increased risk of developing extrapyramidal symptoms and depressive symptoms. Official guidance suggests a lower daily dose when beginning treatment in this age group.

Q: Can Sibelium cause sleeping problems?

A: While the drug is known to cause drowsiness, regulatory documents also report insomnia (difficulty falling or staying asleep) as an infrequently reported side effect.

Q: Are there any official warnings about Sibelium and pregnancy?

A: Official regulatory documents generally state that the use of Sibelium is not recommended during pregnancy or while breastfeeding. Official guidance specifies that the need for treatment must be evaluated by a healthcare provider if a patient is pregnant or planning to be.

Q: Is it true that Sibelium can increase appetite?

A: Yes, regulatory documents list increased appetite as a common side effect.

Q: What is the half-life of Sibelium in the body?

A: Pharmacokinetic data from official regulatory documents indicate that the mean terminal elimination half-life of flunarizine is approximately 18 days. This long half-life supports its use as a once-daily preventative medication.

How should Sibelium be stored and disposed of?

How to Store and Dispose of Sibelium?

The storage and disposal of Sibelium (flunarizine) must strictly adhere to the conditions documented in the official regulatory label to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Do not store above 30°C.
Protection	Store in the original package to protect from light and moisture.
Shelf-Life	The official stability period is 5 years.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Sibelium tablets must be disposed of in accordance with local requirements for medicinal waste. It is mandatory to avoid disposing of the product in household waste or wastewater, which helps prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.